|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash in escrow | |||||||
| Prepaid expenses | |||||||
| Deferred offering costs | |||||||
| Due from Sponsor | |||||||
| Total current assets | |||||||
| Noncurrent assets: | |||||||
| Marketable securities | |||||||
| Total noncurrent assets | |||||||
| Total assets | |||||||
| Liabilities and shareholders’ deficit | |||||||
| Current liabilities: | |||||||
| Accrued liabilities | |||||||
| Due to Sponsor | |||||||
| Other payable | |||||||
| Promissory note payable to Sponsor | |||||||
| Total current liabilities | |||||||
| Deferred underwriting commissions | |||||||
| Deferred underwriting commissions | |||||||
| Total noncurrent liabilities | |||||||
| Total liabilities | |||||||
| Ordinary shares subject to possible redemption, 2,502,021 and 6,900,000 shares at redemption value of $11.12 and $10.44 per share, respectively, including interest and dividends earned in Trust Account | |||||||
| Shareholders’ deficit: | |||||||
| Ordinary shares, $0.001 par value; 50,000,000 shares authorized; and 2,032,000 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | |||||||
| Additional paid-in capital | |||||||
| Accumulated deficit | |||||||
| Total shareholders’ deficit | |||||||
| Total liabilities and shareholders’ deficit |
Loading...